Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions

被引:31
作者
Shibata, Hiroko [1 ]
Izutsu, Ken-ichi [1 ]
Yomota, Chikako [1 ]
Okuda, Haruhiro [1 ]
Goda, Yukihiro [1 ]
机构
[1] Natl Inst Hlth Sci, Div Drugs, Setagaya Ku, Tokyo 1588501, Japan
关键词
Ammonium sulfate; doxorubicin; in vitro drug release; liposome; PEGylated; pH; ultrasound; DRUG-RELEASE; PH; LYSOPHOSPHOLIPIDS; PERFORMANCE; ULTRASOUND; RETENTION; VESICLES; STRENGTH; LESSONS; DRIVEN;
D O I
10.3109/03639045.2014.954582
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Establishing appropriate drug release testing methods of liposomal products for assuring quality and performance requires the determination of factors affecting in vitro drug release. In this study, we investigated the effects of test conditions (human plasma lot, pH/salt concentration in the test media, dilution factor, temperature, ultrasound irradiation, etc.), and liposomal preparation conditions (pH/concentration of ammonium sulfate solution), on doxorubicin (DXR) release from PEGylated liposomal DXR. Higher temperature and lower pH significantly increased DXR release. The evaluation of DXR solubility indicated that the high DXR release induced by low pH may be attributed to the high solubility of DXR at low pH. Ultrasound irradiation induced rapid DXR release in an amplitude-dependent manner. The salt concentration in the test solution, human plasma lot, and dilution factor had a limited impact on DXR-release. Variations in the ammonium sulfate concentration used in solutions for the formation/hydration of liposomes significantly affected DXR release behavior, whereas differences in pH did not. In addition, heating condition in phosphate-buffered saline at lower pH (56.5) exhibited higher discriminative ability for the release profiles from various liposomes with different concentrations of ammonium sulfate than did ultrasound irradiation. These results are expected to be helpful in the process of establishing appropriate drug release testing methods for PEGylated liposomal DXR.
引用
收藏
页码:1376 / 1386
页数:11
相关论文
共 43 条
[1]   Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I [J].
Abdel-Mottaleb, Mona M. A. ;
Lamprecht, Alf .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2011, 37 (02) :178-184
[2]   IN-VITRO TESTS TO PREDICT IN-VIVO PERFORMANCE OF LIPOSOMAL DOSAGE FORMS [J].
AMSELEM, S ;
COHEN, R ;
BARENHOLZ, Y .
CHEMISTRY AND PHYSICS OF LIPIDS, 1993, 64 (1-3) :219-237
[3]  
[Anonymous], 2003, AAPS PharmSciTech, DOI DOI 10.1208/PT040107
[4]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[5]   A novel USP apparatus 4 based release testing method for dispersed systems [J].
Bhardwaj, Upkar ;
Burgess, Diane J. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 388 (1-2) :287-294
[6]  
Burgess DJ, 2002, AAPS PHARMSCI, V4
[7]   Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer [J].
Charrois, GJR ;
Allen, TM .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2004, 1663 (1-2) :167-177
[8]   Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC [J].
Chen, Jun ;
Cheng, Dong ;
Li, Jun ;
Wang, Yong ;
Guo, Jian-xin ;
Chen, Zhi-peng ;
Cai, Bao-chang ;
Yang, Tao .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (02) :197-204
[9]   Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes [J].
Davidsen, J ;
Mouritsen, OG ;
Jorgensen, K .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2002, 1564 (01) :256-262
[10]  
EMA (European Medicines Agency), 2013, REFL PAP DAT REQ INT